CLAIMS

1. Use of an anti-human tau antibody in the manufacture of a medicament for the treatment of Alzheimer's disease in a human subject in need thereof, wherein the medicament is to be administered intravenously to the human subject at a fixed dose of 2000 mg of the anti-human tau antibody once every four weeks, and wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:

   (a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:

   VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;

   VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and

   VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and

   (b) the VL comprises VL-CDRs, wherein:

   VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;

   VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and

   VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21.

2. The use of claim 1, wherein the VH consists of SEQ ID NO:12 and the VL consists of SEQ ID NO:13.

3. The use of claim 1 or claim 2, wherein the anti-human tau antibody comprises a heavy chain and a light chain, wherein the heavy chain consists of SEQ ID NO:14 and the light chain consists of SEQ ID NO:15.

4. A pharmaceutical composition comprising:

   (i) an anti-human tau antibody at a concentration of 50 mg/ml,

   (ii) histidine at a concentration of 20 mM,

   (iii) sucrose at a concentration of 250 mM,

   (iv) polysorbate-80 at a concentration of 0.05% (w/v), and

   (v) 50 µM diethylenetriamine pentaacetic acid (DTPA)

   wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:

(a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:

VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;

VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and

VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and

(b) the VL comprises VL-CDRs, wherein:

VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;

VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and

VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21, and

wherein the composition has a pH of 6.0.

5. The pharmaceutical composition of claim 4, wherein the VH consists of SEQ ID NO:12 and the VL consists of SEQ ID NO:13.

6. The pharmaceutical composition of claim 4, wherein the anti-human tau antibody comprises a heavy chain and a light chain, wherein the heavy chain consists of SEQ ID NO:14 and the light chain consists of SEQ ID NO:15.

7. Use of the pharmaceutical composition of any one of claims 4 to 6 in the manufacture of a medicament for the treatment of Alzheimer's disease in a human subject in need thereof, wherein the medicament is to be administered intravenously to the human subject.

8. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 150 mg once every four weeks.

9. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 210 mg once every four weeks.

10. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 700 mg once every four weeks.

11. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 2000 mg once every four weeks.

12. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 2100 mg once every four weeks.

13. The use of claim 7, wherein the medicament is to be administered at a fixed dose of 4200 mg once every four weeks.

14. The use of any one of claims 7 to 13, wherein the medicament is to be administered for at least 12 weeks.

15. An anti-human tau antibody at a fixed dose of 2000 mg for use in the treatment of Alzheimer's disease, wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:

(a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:

VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;

VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and

VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and

(b) the VL comprises VL-CDRs, wherein:

VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;

VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and

VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21.

16. A pharmaceutical composition for use in the treatment of Alzheimer's disease, wherein the pharmaceutical composition comprises:

(i) an anti-human tau antibody at a concentration of 50 mg/ml,

(ii) histidine at a concentration of 20 mM,

(iii) sucrose at a concentration of 250 mM,

(iv) polysorbate-80 at a concentration of 0.05% (w/v), and

(v) 50 μM diethylenetriamine pentaacetic acid (DTPA)

wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein:

(a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein:

VH-CDR1 consists of the amino acid sequence of SEQ ID NO:16;

VH-CDR2 consists of the amino acid sequence of SEQ ID NO:17; and

VH-CDR3 consists of the amino acid sequence of SEQ ID NO:18; and

(b) the VL comprises VL-CDRs, wherein:

VL-CDR1 consists of the amino acid sequence of SEQ ID NO:19;

VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20; and

VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21, and

wherein the composition has a pH of 6.0.